{
  "url": "https://openlegislation.uk/misuse-of-drugs-amendments-cannabis-and-licence-fees-england-wales-and-scotland-regulations-2018/regulation-3",
  "json_url": "https://openlegislation.uk/misuse-of-drugs-amendments-cannabis-and-licence-fees-england-wales-and-scotland-regulations-2018/regulation-3.json",
  "legislation": "uksi/2018/1055",
  "legislation_title": "The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018",
  "legislation_url": "https://openlegislation.uk/misuse-of-drugs-amendments-cannabis-and-licence-fees-england-wales-and-scotland-regulations-2018",
  "path": "regulation/3",
  "kind": "regulation",
  "number": "3",
  "heading": "Amendment of regulation 2 of the 2001 Regulations",
  "text": "In regulation 2(1) of the 2001 Regulations (interpretation) at the appropriate places insert—\n““cannabis-based product for medicinal use in humans” means a preparation or other product, other than one to which paragraph 5 of part 1 of Schedule 4 applies, which—\n(a) is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers);\n(b) is produced for medicinal use in humans; and—\n(c) is—\n(i) a medicinal product, or\n(ii) a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product;”;\n““clinical trial” has the same meaning as in the Medicines for Human Use (Clinical Trials) Regulations 2004;”;\n““dronabinol” does not include any substance which—\n(a) has the international non-proprietary name dronabinol (recommended by the World Health Organisation); and\n(b) is derived from cannabis, cannabis resin or their constituents,\nand stereoisomers of dronabinol are to be construed accordingly;; and”; and\n““medicinal product” has the same meaning as in the Human Medicines Regulations 2012;”.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "footnote",
      "label": "f1",
      "text": "Regulation 2 has been amended by S.I. 2003/1653, 2003/2429, 2004/1771, 2005/271, 2005/2864, 2006/986, 2006/1450, 2006/2178, 2007/2154, 2011/2581, 2012/973, 2012/1916, 2013/235, 2015/891 and 2018/682."
    },
    {
      "type": "footnote",
      "label": "f2",
      "text": "S.I. 2004/1031. See the definition of “clinical trial” in regulation 2."
    },
    {
      "type": "footnote",
      "label": "f3",
      "text": "S.I. 2012/1916. See the definition of “medicinal product” in regulation 2."
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2018/1055/regulation/3",
    "retrieved_at": "2026-10-28T22:53:35.921317+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}